Short-term survivorship of Truliant total knee arthroplasty implants utilizing the American Joint Replacement Registry.

BACKGROUND

Truliant posterior stabilized (PS) and Truliant cruciate retaining (CR) are two designs used for total knee arthroplasty. Survivorship and reason for revision rates are now available from the American Joint Replacement Registry (AJRR) at short-term time points for both Truliant designs. It was hypothesized that Truliant PS and Truliant CR perform comparably to similar designs in terms of survivorship.

AIM

To analyze short-term survivorship of Truliant PS or CR total knee arthroplasty relative to non-Truliant PS or CR total knee arthroplasty.

METHODS

Utilizing data from the AJRR, a retrospective review was performed for subjects who underwent implantation of Truliant PS, Truliant CR, non-Truliant PS, and non-Truliant CR designs as of June 30, 2022. Survivorship and reasons for revision were compared statistically between Truliant PS non-Truliant PS as well as Truliant CR non-Truliant CR groups. Cumulative percent revision rates were compared across three registries, AJRR, Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR), and the United Kingdom National Joint Registry (UK NJR).

RESULTS

Truliant PS survivorship was 97.95% at the four-year mark, while Truliant CR survivorship was 99.61% at the three-year mark. There were no significant differences in survivorship hazard ratios or reasons for revision for both Truliant groups non-Truliant comparison aggregate groups at short-term time points. Cumulative percent revision rate comparisons were made to device appropriate groups from AJRR, AOANJRR, and UK NJR data. Truliant PS cumulative percent revision rates were similar to non-Truliant cumulative percent revision rates in the AJRR and similar to AOANJRR and UKNJR at both one and three years. Truliant CR cumulative percent revision rates were lower than aggregate AJRR, AOANJRR, and UK NJR cumulative percent revision rates at the one-year and three-year marks.

CONCLUSION

This study demonstrates high survivorship for Truliant PS total knee arthroplasty out to four-years and Truliant CR total knee arthroplasty out to three-years of follow-up.